Trial Profile
Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Biomarker; Therapeutic Use
- Acronyms MB
- 04 Feb 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 28 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 Jan 2011 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.